Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_1760
Pages: 211
Nov 2017 | 9059 Views
face gplus_n
Author's : Onkar Sumant & Sohail Shaikh
Tables: 107
Charts: 41
twit_n pr_n

Protein Therapeutics Market Overview:

Global Protein Therapeutics Market accounted for $140,109 million in 2016, and is anticipated to reach $217,591 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. Therapeutic protein drugs are an important class of medicines, which are administered to treat an array of different diseases such as cancer, infectious diseases, and others. These drugs hold significant potential to improve human health.

The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic diseases and development of plasma-derived therapies. Furthermore, surge in awareness with respect to protein therapeutics among populace boosts the market growth. However, high costs associated with therapeutic proteins and stringent government regulations towards protein therapeutics restrict market growth. Conversely, adoption of protein therapeutics for novel indications and untapped potential of developing countries are anticipated to provide lucrative opportunities to the market players.

The protein therapeutics industry is segmented based product, application, and geography. Depending on product, the market is divided into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle stimulating hormone. The applications covered in this study include metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get more information on this report : Request Sample Pages

North America generated the highest revenue in the protein therapeutics industry in 2016. Asia-Pacific possesses high market potential, owing to increase in awareness about protein therapeutics-based treatments and rise in protein therapeutics applications.

Get more information on this report : Request Sample Pages

Monoclonal antibodies occupied the largest share in the global market, owing to the necessity and applicability of these products in the treatment of different chronic disorders.

Get more information on this report : Request Sample Pages

The report provides extensive competitive analysis and profiles of key market players, such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi. Other players (profiles not included in the report) in the value chain analysis include Biogen, Inc., CSL Behring, and Genentech, Inc.

Key Benefits

  • The study provides an in-depth analysis of the global market, with current trends and future estimations to elucidate the imminent investment pockets.
  • A quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities is discussed.
  • Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the market.
  • Porter’s Five Forces model interprets the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition in the key players.

Protein Therapeutics Market Key Segments:

By Product

  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone

By Application

  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders,
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCE ANALYSIS
3.4. GOVERNMENT REGULATIONS
3.5. TOP PLAYER POSITIONING
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in healthcare expenditure
3.6.1.2. Increase in R&D investments
3.6.1.3. Growth in proteomics research
3.6.1.4. Rise in incidence of chronic diseases

3.6.2. Restraints

3.6.2.1. High production costs

3.6.3. Opportunities

3.6.3.1. Training for professionals
3.6.3.2. Greater potency with reduced costs and increasing affordability
3.6.3.3. Untapped emerging markets

Chapter: 4 PROTEIN THERAPEUTICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MONOCLONAL ANTIBODY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. FUSION PROTEIN

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. ERYTHROPOIETIN

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. INTERFERON

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. HUMAN GROWTH HORMONE

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast

4.8. FOLLICLE-STIMULATING HORMONE

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

Chapter: 5 PROTEIN THERAPEUTICS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. METABOLIC DISORDERS

5.2.1. Market size and forecast

5.3. IMMUNOLOGICAL DISORDERS

5.3.1. Market size and forecast

5.4. HEMATOLOGICAL DISORDERS

5.4.1. Market size and forecast

5.5. CANCER

5.5.1. Market size and forecast

5.6. HORMONAL DISORDERS

5.6.1. Market size and forecast

5.7. GENETIC DISORDERS

5.7.1. Market size and forecast

5.8. OTHERS

5.8.1. Market size and forecast

Chapter: 6 PROTEIN THERAPEUTICS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast, by country

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast, by country
6.2.4. Market size and forecast, by product
6.2.5. Market size and forecast, by application

6.2.5.1. U.S. market size and forecast, by product
6.2.5.2. U.S. market size and forecast, by application
6.2.5.3. Canada market size and forecast, by product
6.2.5.4. Canada market size and forecast, by application
6.2.5.5. Mexico market size and forecast, by product
6.2.5.6. Mexico market size and forecast, by application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast, by country
6.3.4. Market size and forecast, by product
6.3.5. Market size and forecast, by application

6.3.5.1. Germany market size and forecast, by product
6.3.5.2. Germany market size and forecast, by application
6.3.5.3. France market size and forecast, by product
6.3.5.4. France market size and forecast, by application
6.3.5.5. UK market size and forecast, by product
6.3.5.6. UK market size and forecast, by application
6.3.5.7. Italy market size and forecast, by product
6.3.5.8. Italy market size and forecast, by application
6.3.5.9. Spain market size and forecast, by product
6.3.5.10. Spain market size and forecast, by application
6.3.5.11. Rest of Europe market size and forecast, by product
6.3.5.12. Rest of Europe market size and forecast, by application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast, by country
6.4.4. Market size and forecast, by product
6.4.5. Market size and forecast, by application

6.4.5.1. Japan market size and forecast, by product
6.4.5.2. Japan market size and forecast, by application
6.4.5.3. China market size and forecast, by product
6.4.5.4. China market size and forecast, by application
6.4.5.5. Australia market size and forecast, by product
6.4.5.6. Australia market size and forecast, by application
6.4.5.7. India market size and forecast, by product
6.4.5.8. India market size and forecast, by application
6.4.5.9. South Korea market size and forecast, by product
6.4.5.10. South Korea market size and forecast, by application
6.4.5.11. Taiwan market size and forecast, by product
6.4.5.12. Taiwan market size and forecast, by application
6.4.5.13. Rest of Asia-Pacific market size and forecast, by product
6.4.5.14. Rest of Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast, by country
6.5.4. Market size and forecast, by product
6.5.5. Market size and forecast, by application

6.5.5.1. Brazil market size and forecast, by product
6.5.5.2. Brazil market size and forecast, by application
6.5.5.3. Saudi Arabia market size and forecast, by product
6.5.5.4. Saudi Arabia market size and forecast, by application
6.5.5.5. South Africa market size and forecast, by product
6.5.5.6. South Africa market size and forecast, by application
6.5.5.7. Rest of LAMEA market size and forecast, by product
6.5.5.8. Rest of LAMEA market size and forecast, by application

Chapter: 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AMGEN, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. HOFFMANN-LA ROCHE AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. JOHNSON & JOHNSON

7.6.1. Company overview
7.6.2. Company Snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. MERCK & CO., INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVO NORDISK A/S

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. PFIZER INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. SANOFI

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. KEY MONOCLONAL ANTIBODIES AND THEIR MANUFACTURERS
TABLE 2. PROTEIN THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. KEY INSULIN PRODUCTS AND THEIR MANUFACTURERS
TABLE 4. PROTEIN THERAPEUTICS MARKET FOR INSULIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. PROTEIN THERAPEUTICS MARKET FOR FUSION PROTEIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. PROTEIN THERAPEUTICS MARKET FOR ERYTHROPOIETIN, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. PROTEIN THERAPEUTICS MARKET FOR INTERFERON, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. PROTEIN THERAPEUTICS MARKET FOR HUMAN GROWTH HORMONE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. PROTEIN THERAPEUTICS MARKET FOR FOLLICLE-STIMULATING HORMONE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT METABOLIC DISORDERS
TABLE 12. PROTEIN THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT IMMUNOLOGICAL DISORDERS
TABLE 14. PROTEIN THERAPEUTICS MARKET FOR IMMUNOLOGIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT HEMATOLOGICAL DISORDERS
TABLE 16. PROTEIN THERAPEUTICS MARKET FOR HEMATOLOGICAL DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT CANCER
TABLE 18. PROTEIN THERAPEUTICS MARKET FOR CANCER, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 19. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT HORMONAL DISORDERS
TABLE 20. PROTEIN THERAPEUTICS MARKET FOR HORMONAL DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT GENETIC DISORDERS
TABLE 22. PROTEIN THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 23. SOME OF THE THERAPEUTIC PROTEINS USED TO TREAT OTHER TYPES OF DISORDERS
TABLE 24. PROTEIN THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 25. PROTEIN THERAPEUTICS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 28. NORTH AMERICA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 29. U.S. PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 30. U.S. PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 31. CANADA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 32. CANADA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. MEXICO PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 34. MEXICO PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. EUROPE PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 36. EUROPE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 37. EUROPE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. GERMANY PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 39. GERMANY PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 40. FRANCE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 41. FRANCE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42. UK PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 43. UK PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. ITALY PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 45. ITALY PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. SPAIN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 47. SPAIN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 51. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 52. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. JAPAN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 54. JAPAN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. CHINA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 56. CHINA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 57. AUSTRALIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 58. AUSTRALIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59. INDIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 60. INDIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 61. SOUTH KOREA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 62. SOUTH KOREA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. TAIWAN PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 64. TAIWAN PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 67. LAMEA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 68. LAMEA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 69. LAMEA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 70. BRAZIL PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 71. BRAZIL PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 72. SAUDI ARABIA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 73. SAUDI ARABIA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 74. SOUTH AFRICA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 75. SOUTH AFRICA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 76. REST OF LAMEA PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 77. REST OF LAMEA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 78. ABBOTT: COMPANY SNAPSHOT
TABLE 79. ABBOTT: OPERATING SEGMENTS
TABLE 80. ABBOTT: PRODUCT PORTFOLIO
TABLE 81. AMGEN: COMPANY SNAPSHOT
TABLE 82. AMGEN: OPERATING SEGMENTS
TABLE 83. AMGEN: PRODUCT PORTFOLIO
TABLE 84. BAXTER: COMPANY SNAPSHOT
TABLE 85. BAXTER: OPERATING SEGMENTS
TABLE 86. BAXTER: PRODUCT PORTFOLIO
TABLE 87. LILLY: COMPANY SNAPSHOT
TABLE 88. LILLY: OPERATING SEGMENTS
TABLE 89. LILLY: OPERATING SEGMENTS
TABLE 90. ROCHE: COMPANY SNAPSHOT
TABLE 91. ROCHE: OPERATING SEGMENT
TABLE 92. ROCHE: PRODUCT PORTFOLIO
TABLE 93. J&J: COMPANY SNAPSHOT
TABLE 94. J&J: OPERATING SEGMENTS
TABLE 95. J&J: PRODUCT PORTFOLIO
TABLE 96. MERCK: COMPANY SNAPSHOT
TABLE 97. MERCK: OPERATING SEGMENTS
TABLE 98. MERCK: PRODUCT PORTFOLIO
TABLE 99. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 100. NOVO NORDISK: OPERATING SEGMENTS
TABLE 101. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 102. PFIZER: COMPANY SNAPSHOT
TABLE 103. PFIZER: OPERATING SEGMENTS
TABLE 104. PFIZER: PRODUCT PORTFOLIO
TABLE 105. SANOFI: COMPANY SNAPSHOT
TABLE 106. SANOFI: OPERATING SEGMENTS
TABLE 107. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. TOP INVESTMENT POCKETS
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF SUBSTITUTION
FIGURE 7. MODERATE THREAT OF NEW ENTRANT
FIGURE 8. MODERATE COMPETITIVE RIVALRY
FIGURE 9. GLOBAL PROTEIN THERAPEUTICS MARKET: TOP PLAYER POSITIONING
FIGURE 10. PROTEIN THERAPEUTICS MARKET: PRODUCT SEGMENTATION
FIGURE 11. GLOBAL PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
FIGURE 12. PROTEIN THERAPEUTICS MARKET: APPLICATION SEGMENTATION
FIGURE 13. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 14. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 15. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 16. AMGEN: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 18. BAXTER: NET SALES, 2014-2016 ($MILLION)
FIGURE 19. BAXTER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 20. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 21. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 23. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 24. ROCHE: REVENUE, 2014-2016 ($MILLION)
FIGURE 25. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 26. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 27. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 31. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 32. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 33. NOVO NORDISK: NET SALES, 2014-2016 ($MILLION)
FIGURE 34. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 35. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 36. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 37. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

Protein therapeutics have positively impacted diverse fields of disease treatment and prognosis. Diseases that were otherwise debilitating and life-threatening can be managed through administration of these drugs. In addition, these drugs have contributed significantly in diagnosis and prevention of oncologic, metabolic, immunologic, and other chronic diseases. Protein therapeutics are expected to witness high adoption with increase in prevalence of distinct indications and interventions such as lymphomas, diabetes, hepatitis, leukemia, and others. Protein therapeutics market has gained momentum in the healthcare industry and pharmaceutical sector, owing to the favorable government policies, conducive regulations abiding protein therapeutics, and growth in proteomics research.

However, high treatment costs per patient, stringent government regulations towards protein therapeutics, and complex reimbursement scenario restrict the market growth. At present, metabolic diseases treatment through protein therapeutics holds the maximum share in the global protein therapeutics market, and is expected to maintain this trend during the study period, due to rise in prevalence of diabetes globally.

Increase in awareness towards protein therapeutics and investment in research, innovation, and drug development fuel the demand for protein therapeutics. The employment of novel protein therapeutics is highest in North America, owing to increase in adoption of these drugs, followed by Europe and Asia-Pacific.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Protein Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo